<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00237445</url>
  </required_header>
  <id_info>
    <org_study_id>HMR3647A_4027</org_study_id>
    <nct_id>NCT00237445</nct_id>
  </id_info>
  <brief_title>Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days</brief_title>
  <acronym>COBRA II</acronym>
  <official_title>A Multinational, Multicenter, Randomized, Double-blind, Study in Areas of High Pneumococcal Resistance Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Ketek® Telithromycin Once Daily for 7 Days, or Zithromax® Azithromycin Once Daily for 5 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal&#xD;
      resistance comparing the clinical efficacy and health outcomes of outpatients with mild to&#xD;
      moderate Community-Acquired Pneumonia (CAP) treated with either telithromycin once daily for&#xD;
      7 days, or azithromycin once daily for 5 days&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate clinical cure rates of telithromycin over azithromycin for treating adult outpatients with mild to moderate community-acquired pneumonia (CAP) in high pneumococcal bacterial resistance areas, at the test of cure visit (Days 17-21).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the effect of telithromycin versus azithromycin on clinical efficacy in CAP adult outpatients at the end of therapy</measure>
  </secondary_outcome>
  <enrollment type="Actual">110</enrollment>
  <condition>Pneumonia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male or female outpatients aged 20 or greater.&#xD;
&#xD;
          -  Subjects with a positive Binax NOW S. pneumoniae Urinary Antigen Test and/or positive&#xD;
             gram stain for diplococci.&#xD;
&#xD;
          -  Subjects with ≤ 7 days of signs and symptoms of CAP.&#xD;
&#xD;
          -  Subjects with chest x-ray findings that support a diagnosis of acute pneumonia with&#xD;
             presence of a new infiltrate. For subjects with history of chronic obstructive&#xD;
             pulmonary disease (COPD), a comparison to previous chest x-ray report is required to&#xD;
             confirm the finding of new infiltrates.&#xD;
&#xD;
        Subjects with diagnosis of acute mild to moderate CAP based on at least one of the&#xD;
        following:&#xD;
&#xD;
          -  fever (oral &gt;37.5°C/99.5°F or axillary &gt;37.4°C/99.4°F or rectal &gt;38.5°C/101.5°F) or&#xD;
&#xD;
          -  elevated total peripheral white blood cell count &gt;10,000/mm3 or &gt;15% immature&#xD;
             neutrophils (bands), regardless of total peripheral white count and&#xD;
&#xD;
          -  new and sudden onset (equal or less than 48 hours) of at least two of the following&#xD;
             signs or symptoms:&#xD;
&#xD;
               -  cough&#xD;
&#xD;
               -  dyspnea or tachypnea (particularly if progressive in nature)&#xD;
&#xD;
               -  pleuritic chest pain&#xD;
&#xD;
               -  purulent sputum production or change in sputum character&#xD;
&#xD;
               -  auscultatory findings (such as rales and/or evidence of pulmonary consolidation)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects presenting with any of the following will not be included in the study.&#xD;
&#xD;
               -  Subjects with CAP requiring hospitalization.&#xD;
&#xD;
               -  Subjects with signs and symptoms of severe CAP lasting greater than 7 days.&#xD;
&#xD;
               -  Subjects requiring parenteral antibiotic treatment.&#xD;
&#xD;
               -  Subjects discharged from hospital within the 10 days before study entry.&#xD;
&#xD;
               -  Subjects with visible/gross aspiration pneumonia.&#xD;
&#xD;
               -  Subjects with any concomitant pulmonary disease, condition or complication that&#xD;
                  could confound the interpretation or evaluation of drug efficacy or safety,&#xD;
                  including:&#xD;
&#xD;
          -  severe bronchiectasis, cystic fibrosis or suspected active pulmonary tuberculosis&#xD;
&#xD;
          -  suspected acute pulmonary embolism&#xD;
&#xD;
          -  emphysema, lung abscess, extra pulmonary extension (e.g., meningitis, septic&#xD;
             arthritis, endocarditis)&#xD;
&#xD;
          -  known bronchial obstruction or a history of postobstructive pneumonia.&#xD;
&#xD;
               -  Subjects with neoplastic lung disease (lung cancer) or another malignancy&#xD;
                  metastatic to the lungs, and/or requiring chemotherapeutic interventions for this&#xD;
                  or other neoplasms.&#xD;
&#xD;
               -  Subjects with infection requiring administration of other systemic antimicrobial&#xD;
                  agents.&#xD;
&#xD;
               -  Subjects with progressively fatal disease; life expectancy ≤3 months.&#xD;
&#xD;
               -  Subjects with myasthenia gravis.&#xD;
&#xD;
               -  Subjects with any concomitant condition, including severe and/or uncontrolled&#xD;
                  cardiovascular, neurologic, endocrine, or other severe and/or uncontrolled major&#xD;
                  systemic disease that make implementation of the protocol or interpretation of&#xD;
                  the study results difficult.&#xD;
&#xD;
               -  Immunocompromised subjects, such as:&#xD;
&#xD;
          -  known HIV subjects with CD4+ T-lymphocyte count dated less than 3 months &lt;200/mm3 and&#xD;
             /or HIV subjects treated with isoniazide or clarithromycin as prophylaxis&#xD;
&#xD;
          -  neutropenia (&lt;1500 neutrophils/mm3) not attributable to the acute infectious disease&#xD;
&#xD;
          -  metastatic or hematological malignancy&#xD;
&#xD;
          -  splenectomy or known hyposplenia or asplenia&#xD;
&#xD;
          -  chronic corticosteroid therapy.&#xD;
&#xD;
               -  Subjects with a history of congenital or a family history of long QT syndrome (if&#xD;
                  not excluded by previous ECG) and subjects with known acquired QT interval&#xD;
                  prolongation&#xD;
&#xD;
               -  Known severe impaired renal function as shown by creatinine clearance &lt; 30 ml/min&#xD;
                  either measured or estimated with Cockroft formula.&#xD;
&#xD;
               -  Subjects who have received more than 24 hours of effective treatment with other&#xD;
                  antibiotics, within the 7 days prior to enrollment in the study.&#xD;
&#xD;
               -  Subjects with a known or suspected hypersensitivity to, or a known or suspected&#xD;
                  serious adverse reaction to telithromycin or any macrolide antibiotic.&#xD;
&#xD;
               -  Subjects who will require on-study treatment with medications known to have&#xD;
                  potential drug interactions, including ergot alkaloids derivatives, terfenadine,&#xD;
                  astemizole, cisapride, pimozide, simvastatin, atorvastatin and lovastatin (see&#xD;
                  Section 6.2).&#xD;
&#xD;
               -  Subjects who have received any investigational drug within 1 month prior to study&#xD;
                  entry or such treatment is planned for during the study period.&#xD;
&#xD;
               -  Subjects who are pregnant or breast-feeding.&#xD;
&#xD;
               -  Subjects with recent drug or alcohol abuse.Subjects with a mental condition&#xD;
                  rendering the subject unable to understand the nature, scope, and possible&#xD;
                  consequences of the study.&#xD;
&#xD;
               -  Subject is the investigator or any subinvestigator, research assistance,&#xD;
                  pharmacist, study coordinator, other staff or relative thereof directly involved&#xD;
                  in the conduct of the protocol.&#xD;
&#xD;
               -  Subjects already enrolled in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>October 10, 2005</study_first_submitted>
  <study_first_submitted_qc>October 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Telithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

